Samsung's drug-manufacturing unit plans to go public

South Korea's Samsung announced Thursday a plan to list shares of its drug-manufacturing unit on Seoul's stock market as it eyes the bio-medical business as a new engine for growth. Samsung Biologics' board members agreed Thursday to list the firm's shares on Seoul's main Kospi bourse by the end of this year in a step to fund more investment, the firm said in a statement. The firm produces biopharmaceutical drugs for major companies including Bristol-Myers Squibb and Roche at plants west of Seou